Condition
Gastrointestinal Neuroendocrine Tumor
Total Trials
4
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Recruiting3
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT05988918Phase 2Recruiting
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
NCT05196087Recruiting
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
NCT05997056Phase 2Recruiting
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
NCT03963193Phase 2UnknownPrimary
Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type
Showing all 4 trials